AdvaMed Signs New MOU with British Medtech Association
WASHINGTON – Today, AdvaMed, the Medtech Association, signed a renewed memorandum of understanding with the Association of British HealthTech Industries (ABHI) to strengthen the relationship between two of the leading medtech organizations in the world. The new MOU, which was first signed by the two organizations in 2020, includes new AI regulatory collaboration, trade and market access policy alignment, and enhanced collaboration around regulatory reliance policy developments.
“AdvaMed is proud to partner with our friends in the United Kingdom to advance our shared goal of improving patient access to lifesaving medical technology,” said Scott Whitaker, AdvaMed President and CEO. “This updated MOU comes as our industry, both at home and abroad, innovates at a rapid pace, producing new technologies and software year after year. Agreements like this are vital to our work to seek new public policy opportunities and address any challenges before they impact our industry. We thank ABHI for their partnership and their leadership in the U.K., and we look forward to working alongside their team for years to come.“
“I am personally very proud of the strengthened partnership between ABHI and AdvaMed. We recognise the strong value that AdvaMed delivers on behalf of the global industry, and this enhanced collaboration will allow us to work together even more closely to support the industry,” said ABHI CEO Peter Ellingworth. “Together, we will drive positive change in the HealthTech sector worldwide, ultimately benefiting patients by improving access to lifesaving technologies.”
The MOU includes many provisions to improve collaboration between the U.S. and U.K. medtech markets, including:
- AI regulatory development
- Regulatory convergence
- Trade and 3rd Party Country engagement
- National Health Service sustainability initiative